<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01925170</url>
  </required_header>
  <id_info>
    <org_study_id>1337-05 Part B</org_study_id>
    <nct_id>NCT01925170</nct_id>
  </id_info>
  <brief_title>Low Dose Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts</brief_title>
  <official_title>Evaluation of Low-dose Molecular Breast Imaging as a Screening Tool in Women With Mammographically Dense Breasts and Increased Risk of Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Susan G. Komen Breast Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A new test for breast cancer screening, molecular breast imaging (MBI) may be more sensitive
      than mammography for detecting breast cancer in women with dense breasts. The purpose of this
      study is to see if MBI using a low dose of gamma radiation can find cancers not seen on
      mammography.

      Hypotheses: 1. Low-Dose MBI has a significantly higher sensitivity and specificity and equal
      or higher positive predictive value than SM in women age 40 and older with mammographically
      dense breasts. 2. Low-dose MBI has comparable sensitivity and specificity to that previously
      achieved with MBI using a higher dose of radiation. 3. MBI produces a low false positive rate
      (specificity &gt;90%) that permits its use as a screening tool in this patient population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A previous study demonstrated that the addition of MBI using 20 mCi Tc-99m sestamibi to
      screening mammography (SM) increased diagnostic yield for breast cancer in dense breasts
      (supplemental yield of 7.5/1000 screened). After implementing radiation dose reduction
      techniques, the performance of incident SM and prevalent screen MBI in women with dense
      breasts will be compared.

      Methods:

      Women presenting for SM with heterogeneously or extremely dense breasts on past prior SM were
      enrolled and underwent digital SM and MBI. Study information was sent to all eligible
      patients in advance of their scheduled SM explaining the study and offering them
      participation. Eligible patients who requested to participate were offered an MBI on the same
      day as their SM or within 21 days of the SM. Participants may have participated in this
      screening study up to two times provided at least 24 months had elapsed since the initial MBI
      scan. This time period was selected as the average time for a tumor to double in size is
      approximately 20 months. Hence a 24 month time interval between MBI studies was to enable
      detection of interval cancers or cancers that were too small to be detected in the initial
      MBI scan.

      MBI was performed with 8 mCi Tc-99m sestamibi and dual-head cadmium zinc telluride detectors.
      SMs were read independently; MBIs were read in comparison with SM. MBIs were assigned an
      assessment score of 1-5 which parallels BI-RADS; scores of 3-5 on MBI were considered
      positive.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cancer Detection Rate Per 1000 Women Screened, by Breast Density</measure>
    <time_frame>Within 21 days of mammography</time_frame>
    <description>The cancer detection rate per 1000 women screened is the estimate of the number of women with positive results from a screening test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specificity</measure>
    <time_frame>Within 21 days of mammography</time_frame>
    <description>Specificity measures the percentage of negatives which are correctly identified as such.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity for All Cancers Diagnosed</measure>
    <time_frame>Within 21 days of mammography</time_frame>
    <description>Sensitivity measures the percentage of actual positives which are correctly identified as such.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recall Rate</measure>
    <time_frame>12 months after mammography and MBI</time_frame>
    <description>Recall rate was defined as the percentage of participants recalled for follow-up studies initiated because of abnormal findings with mammography or MBI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biopsy Rate</measure>
    <time_frame>12 months after mammography and MBI</time_frame>
    <description>Biopsy rate = number of participants who had a biopsy/number of number of participants analyzed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1638</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Mammography and Molecular Breast Imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants underwent conventional mammography and molecular breast imaging after a 740-millibecquerel (mBQ) (8-mCi) Technetium (99mTc) sestamibi injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Molecular Breast Imaging</intervention_name>
    <description>Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.</description>
    <arm_group_label>Mammography and Molecular Breast Imaging</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conventional Mammography</intervention_name>
    <description>Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.</description>
    <arm_group_label>Mammography and Molecular Breast Imaging</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Technetium (99mTc) sestamibi</intervention_name>
    <description>Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.</description>
    <arm_group_label>Mammography and Molecular Breast Imaging</arm_group_label>
    <other_name>Cardiolite</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Past prior SM interpreted as negative or benign [Breast Imaging Reporting and Data
             System (BI-RADS) Category 1 or 2]

          -  Past prior SM interpreted as heterogeneously dense or extremely dense

        Exclusion Criteria:

          -  Subject is unable to understand and sign the consent form

          -  Subject is pregnant or lactating

          -  Subject is physically unable to sit upright and still for 40 minutes

          -  Subject has self-reported signs or symptoms of breast cancer (palpable mass, bloody
             nipple discharge, axillary mass, etc.)

          -  Subject has had needle biopsy within 3 months, or breast surgery within 1 year prior
             to the study

          -  Subject is currently taking tamoxifen, Evista (raloxifene), Zoladex or an aromatase
             inhibitor for adjuvant therapy or chemoprevention.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah J Rhodes, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.gov/show/NCT00620373</url>
    <description>1337-05 Part A, High-Dose Molecular Breast Imaging</description>
  </link>
  <reference>
    <citation>Rhodes DJ, Hruska CB, Phillips SW, Whaley DH, O'Connor MK. Dedicated dual-head gamma imaging for breast cancer screening in women with mammographically dense breasts. Radiology. 2011 Jan;258(1):106-18. doi: 10.1148/radiol.10100625. Epub 2010 Nov 2.</citation>
    <PMID>21045179</PMID>
  </reference>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2013</study_first_submitted>
  <study_first_submitted_qc>August 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2013</study_first_posted>
  <results_first_submitted>May 29, 2014</results_first_submitted>
  <results_first_submitted_qc>July 30, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 19, 2014</results_first_posted>
  <last_update_submitted>July 30, 2014</last_update_submitted>
  <last_update_submitted_qc>July 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Deborah Rhodes</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Dense breast tissue</keyword>
  <keyword>Breast Cancer Screening</keyword>
  <keyword>Molecular Breast Imaging</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Breast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Technetium Tc 99m Sestamibi</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Women for the Part B low dose study were enrolled between 5/11/2009 and 3/8/2012.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Mammography and Molecular Breast Imaging</title>
          <description>Participants underwent conventional mammography and molecular breast imaging after a 740-millibecquerel (mBQ) (8-mCi) Technetium (99mTc) sestamibi injection.
Molecular Breast Imaging: Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
Conventional Mammography: Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.
Technetium (99mTc) sestamibi: Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1638"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1585"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unverified cancer status</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mammography and Molecular Breast Imaging</title>
          <description>Participants underwent conventional mammography and molecular breast imaging after a 740-millibecquerel (mBQ) (8-mCi) Technetium (99mTc) sestamibi injection.
Molecular Breast Imaging: Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
Conventional Mammography: Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.
Technetium (99mTc) sestamibi: Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1638"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>At the beginning of the study, the protocol inclusion criteria allowed women aged 25 years and older to participate. Between the dates of 5/11/09 and 4/20/10 there were 13 women under age 40 enrolled. On 4/20/2010 a protocol revision was approved by the Institutional Review Board to allow women aged 40 and older. In the final analyzable dataset of 1585 women who completed the study and had reference standard, 6 women were under age 40.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.1" lower_limit="31" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menopausal Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Premenopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peri-menopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical Menopause</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mammographic Breast Density</title>
          <description>Eligibility was determined by density assessed on a previous mammogram prior to study entry; mammographic density reported refers to density assessed from the study mammogram.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Almost entirely fat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scattered fibroglandular densities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heterogeneously dense</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely dense</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Risk Factors</title>
          <description>Although participants may have qualified for multiple risk factor categories, they were assigned to only one risk factor category in this table. These risk factors are listed in order of priority. The last two risk factors with respect to first and second-degree relatives with a history of breast cancer refer to subjects who qualified on the basis of family history but did not meet the Gail or Claus model risk threshold levels.
The Gail risk model focuses on nongenetic risk factors, with limited information on family history. The Claus risk model focuses on genetic risk factors.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Known mutation in BRCA1 or BRCA2 genes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest, mediastinal, or axillary irradiation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Personal history of breast cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prior biopsy showing hyperplasia, etc.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gail or Claus model lifetime risk ≥ 20%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gail model 5 year risk ≥ 2.5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gail model 5 year risk ≥ 1.7%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 first-deg relative with history of breast cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 2nd-deg relatives with history of breast cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None of the above risk factors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mammogram Prior to Study Entry</title>
          <description>A total of 7 women under the age of 50 with no prior mammogram were enrolled.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 425 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>425-730 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;730 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Molecular Breast Imaging Prior to Study Entry</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 425 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>415- 730 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 730 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Breast Density of Participants with No Prior Mammogram</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Scattered fibroglandular densities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heterogeneously dense breasts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with Prior Mammogram</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cancer Detection Rate Per 1000 Women Screened, by Breast Density</title>
        <description>The cancer detection rate per 1000 women screened is the estimate of the number of women with positive results from a screening test.</description>
        <time_frame>Within 21 days of mammography</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mammography Only</title>
            <description>For this reporting arm, the interpretation and analysis was done with mammography only.</description>
          </group>
          <group group_id="O2">
            <title>Mammography With Adjunct MBI</title>
            <description>For this reporting arm, the interpretation and analysis was done with both mammography and MBI together.</description>
          </group>
          <group group_id="O3">
            <title>Molecular Breast Imaging Alone</title>
            <description>For this reporting arm, the interpretation and analysis was done with gamma imaging only.</description>
          </group>
        </group_list>
        <measure>
          <title>Cancer Detection Rate Per 1000 Women Screened, by Breast Density</title>
          <description>The cancer detection rate per 1000 women screened is the estimate of the number of women with positive results from a screening test.</description>
          <units>cancers per 1000 women screened</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1585"/>
                <count group_id="O2" value="1585"/>
                <count group_id="O3" value="1585"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All densities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="1.3" upper_limit="7.4"/>
                    <measurement group_id="O2" value="12.0" lower_limit="7.7" upper_limit="18.6"/>
                    <measurement group_id="O3" value="10.7" lower_limit="6.7" upper_limit="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scattered fibroglandular densities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="26.2"/>
                    <measurement group_id="O2" value="21.0" lower_limit="7.2" upper_limit="59.9"/>
                    <measurement group_id="O3" value="21.0" lower_limit="7.2" upper_limit="59.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heterogeneously dense</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="1.3" upper_limit="8.4"/>
                    <measurement group_id="O2" value="10.6" lower_limit="6.2" upper_limit="18.1"/>
                    <measurement group_id="O3" value="9.0" lower_limit="5.0" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely dense</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="0.2" upper_limit="25.2"/>
                    <measurement group_id="O2" value="13.6" lower_limit="4.6" upper_limit="39.1"/>
                    <measurement group_id="O3" value="13.6" lower_limit="4.6" upper_limit="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of the two groups for all densities, significant difference p ≤ 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of two groups for all densities; significant difference p ≤ 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Specificity</title>
        <description>Specificity measures the percentage of negatives which are correctly identified as such.</description>
        <time_frame>Within 21 days of mammography</time_frame>
        <population>The analysis population only included participants with a verified negative cancer status at 12 months after the initial screening (mammography and MBI).</population>
        <group_list>
          <group group_id="O1">
            <title>Mammography Only</title>
            <description>For this reporting arm, the interpretation and analysis was done with mammography only.</description>
          </group>
          <group group_id="O2">
            <title>Mammography With Adjunct MBI</title>
            <description>For this reporting arm, the interpretation and analysis was done with both mammography and MBI together.</description>
          </group>
          <group group_id="O3">
            <title>Molecular Breast Imaging Alone</title>
            <description>For this reporting arm, the interpretation and analysis was done with gamma imaging only.</description>
          </group>
        </group_list>
        <measure>
          <title>Specificity</title>
          <description>Specificity measures the percentage of negatives which are correctly identified as such.</description>
          <population>The analysis population only included participants with a verified negative cancer status at 12 months after the initial screening (mammography and MBI).</population>
          <units>percentage of true negatives</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1564"/>
                <count group_id="O2" value="1564"/>
                <count group_id="O3" value="1564"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.1" lower_limit="87.5" upper_limit="90.6"/>
                    <measurement group_id="O2" value="83.4" lower_limit="81.4" upper_limit="85.1"/>
                    <measurement group_id="O3" value="93.5" lower_limit="92.1" upper_limit="94.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Significant difference p ≤ 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Significant difference p ≤ 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensitivity for All Cancers Diagnosed</title>
        <description>Sensitivity measures the percentage of actual positives which are correctly identified as such.</description>
        <time_frame>Within 21 days of mammography</time_frame>
        <population>The analysis population only included participants with a verified cancer status at 12 months after the initial screening. 21 participants out of the total study population of 1585 were diagnosed with cancer.</population>
        <group_list>
          <group group_id="O1">
            <title>Mammography Only</title>
            <description>For this reporting arm, the interpretation and analysis was done with mammography only.</description>
          </group>
          <group group_id="O2">
            <title>Mammography With Adjunct MBI</title>
            <description>For this reporting arm, the interpretation and analysis was done with both mammography and MBI together.</description>
          </group>
          <group group_id="O3">
            <title>Molecular Breast Imaging Alone</title>
            <description>For this reporting arm, the interpretation and analysis was done with gamma imaging only.</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity for All Cancers Diagnosed</title>
          <description>Sensitivity measures the percentage of actual positives which are correctly identified as such.</description>
          <population>The analysis population only included participants with a verified cancer status at 12 months after the initial screening. 21 participants out of the total study population of 1585 were diagnosed with cancer.</population>
          <units>percentage of actual positives</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8" lower_limit="10.6" upper_limit="45.1"/>
                    <measurement group_id="O2" value="90.5" lower_limit="71.1" upper_limit="97.3"/>
                    <measurement group_id="O3" value="81.0" lower_limit="60.0" upper_limit="91.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Significant difference p ≤ 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Significant difference p ≤ 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recall Rate</title>
        <description>Recall rate was defined as the percentage of participants recalled for follow-up studies initiated because of abnormal findings with mammography or MBI.</description>
        <time_frame>12 months after mammography and MBI</time_frame>
        <population>The analysis population only included participants with a verified cancer status at 12 months after the initial screening (mammography and MBI).</population>
        <group_list>
          <group group_id="O1">
            <title>Mammography Only</title>
            <description>For this reporting arm, the interpretation and analysis was done with mammography only.</description>
          </group>
          <group group_id="O2">
            <title>Mammography With Adjunct MBI</title>
            <description>For this reporting arm, the interpretation and analysis was done with both mammography and MBI together.</description>
          </group>
          <group group_id="O3">
            <title>Molecular Breast Imaging Alone</title>
            <description>For this reporting arm, the interpretation and analysis was done with gamma imaging only.</description>
          </group>
        </group_list>
        <measure>
          <title>Recall Rate</title>
          <description>Recall rate was defined as the percentage of participants recalled for follow-up studies initiated because of abnormal findings with mammography or MBI.</description>
          <population>The analysis population only included participants with a verified cancer status at 12 months after the initial screening (mammography and MBI).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1585"/>
                <count group_id="O2" value="1585"/>
                <count group_id="O3" value="1585"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" lower_limit="9.6" upper_limit="12.7"/>
                    <measurement group_id="O2" value="17.6" lower_limit="15.8" upper_limit="19.6"/>
                    <measurement group_id="O3" value="7.5" lower_limit="6.3" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Significant difference p ≤ 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Significant difference p ≤ 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biopsy Rate</title>
        <description>Biopsy rate = number of participants who had a biopsy/number of number of participants analyzed.</description>
        <time_frame>12 months after mammography and MBI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mammography Only</title>
            <description>For this reporting arm, the interpretation and analysis was done with mammography only.</description>
          </group>
          <group group_id="O2">
            <title>Mammography With Adjunct MBI</title>
            <description>For this reporting arm, the interpretation and analysis was done with both mammography and MBI together.</description>
          </group>
          <group group_id="O3">
            <title>Molecular Breast Imaging Alone</title>
            <description>For this reporting arm, the interpretation and analysis was done with gamma imaging only.</description>
          </group>
        </group_list>
        <measure>
          <title>Biopsy Rate</title>
          <description>Biopsy rate = number of participants who had a biopsy/number of number of participants analyzed.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1585"/>
                <count group_id="O2" value="1585"/>
                <count group_id="O3" value="1585"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.8" upper_limit="1.9"/>
                    <measurement group_id="O2" value="4.2" lower_limit="3.3" upper_limit="5.3"/>
                    <measurement group_id="O3" value="3.2" lower_limit="2.5" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Significant difference p ≤ 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Significant difference p ≤ 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were followed for adverse events while they were on the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mammography and Molecular Breast Imaging</title>
          <description>Participants underwent conventional mammography and molecular breast imaging after a 740-millibecquerel (mBQ) (8-mCi) Technetium (99mTc) sestamibi injection.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1585"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1585"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Deborah Rhodes</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-7971</phone>
      <email>rhodes.deborah@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

